Solvonis Therapeutics has signed a non-binding memorandum of understanding with Portugal's national addiction institute and a Lisbon clinic operator to assess adding Portuguese sites to the UK Phase 3 MORE-KARE trial of SVN-001 in severe alcohol use disorder. Any participation would still need a series of approvals and funding agreements.
What was announced
Solvonis Therapeutics plc (LSE:SVNS) said on 13 October 2026 that it had signed a memorandum of understanding (MoU) with two Portuguese parties to assess the potential expansion of MORE-KARE, the Phase 3 trial of its SVN-001 treatment, into Portugal.
The first party is ICAD (Instituto para os Comportamentos Aditivos e as Dependências, I.P.), Portugal's public addiction institute, which sits within the Ministry of Health. ICAD will help assess addiction treatment services, referral pathways and patient recruitment. The second is Panegreen – Health & Wellness Solutions, Lda., which operates The Clinic of Change, a ketamine-assisted psychotherapy clinic in Lisbon. Panegreen will coordinate the Portuguese work.
The MoU is explicitly non-binding. According to the announcement, it "does not create a binding commitment to proceed with Portuguese trial participation". It has an initial term of six months.
Scope of the assessment
The parties will examine potential investigators and trial sites; recruitment, treatment delivery, staffing and training; pharmacy and controlled-drug requirements; translation of trial materials; Portuguese regulatory and ethics requirements; and start-up timelines and indicative costs.
Solvonis said the aim is to add EU patient data that could strengthen future applications for marketing authorisation in selected EU countries or across the EU. It will also assess whether Portuguese sites could operate at a cost per participant "broadly in line with" that of the NHS sites in MORE-KARE. No cost figures were given for either the assessment or any Portuguese sites, and the company said final costs and funding arrangements remain subject to agreement.
Any Portuguese participation would require agreement from the trial sponsor and funders, as well as ethics, regulatory, contractual, funding and governance approvals. Solvonis said it will take the proposal to the University of Exeter, the NIHR and the MRC, whose consideration will be informed by the assessment.
The trial
MORE-KARE is a UK Phase 3 trial evaluating SVN-001, which combines ketamine with structured psychological therapy, in severe alcohol use disorder. The trial involves 280 participants at NHS sites. It is sponsored by the University of Exeter and co-funded by Solvonis, the NIHR and the MRC. The announcement does not set out the trial's endpoints or expected readout timing, and gives no timetable for a decision on Portuguese participation.
Chief executive Anthony Tennyson said: "Signing this MoU moves our European plans forward," adding that the focus is on "patients, treatment capacity, timelines and costs". Dr Renata Crome, an independent non-executive director and former global head of development operations at Roche, said Portugal "was one of the first countries we would consider" when adding international sites to trials, and described ICAD and The Clinic of Change as "exactly the partners I would want for that".
Background and what to watch
The MoU follows the European expansion plan that Solvonis announced on 25 August 2026 and reiterated on 29 September 2026. The company said the agreement marks a move from plan to signed framework in under two months.
The main points to watch are the outcome of the six-month assessment, the response of the University of Exeter, NIHR and MRC, and whether funding and regulatory approvals for Portuguese sites can be secured. Solvonis said it will update the market as appropriate. Turner Pope Investments is the company's corporate broker.






Please wait processing your request...